Genetically Modified Haploidentical Natural Killer Cell Infusions for B-Lineage Acute Lymphoblastic Leukemia

Inclusion Criteria:

* Age: less than or equal to 18 years of age. May be greater than 18 years of age if currently a St. Jude patient.
* Patients with relapsed or refractory B-lineage ALL who are not eligible for hematopoietic stem cell transplantation (HSCT) because their leukemia is not in remission (\>5% blasts in bone marrow as evidenced either by morphology or by flow cytometry).
* Shortening fraction greater than or equal to 25%.
* Glomerular filtration rate greater than or equal to 50 cc/min/1.73 m2.
* Pulse oximetry greater than or equal to 92% on room air.
* Direct bilirubin less than or equal to 3.0 mg/dL.
* Alanine aminotransferase (ALT) is no more than 2 times the upper limit of normal.
* Aspartate transaminases (AST) is no more than 2 times the upper limit of normal.
* Karnofsky or Lansky performance score of greater than or equal to 50.
* No known allergy to murine products or HAMA testing results within normal limits.
* No prior receipt of a gene-transfer agent (e.g. retroviral, adenoviral, lentiviral vector).
* Does not have a current pleural or pericardial effusion.
* Has a suitable adult family member donor available for NK cell donation.
* Has recovered from all acute NCI Common Toxicity Criteria grade II-IV non-hematologic acute toxicities resulting from previous therapy as per the judgment of the principal investigator.
* At least two weeks since receipt of any biological therapy, systemic chemotherapy, and/or radiation therapy.
* Is not receiving more than the equivalent of prednisone 10 mg daily.

Exclusion Criteria:

* Pregnant (negative serum or urine pregnancy test to be conducted within 7 days prior to enrollment)
* Breastfeeding